Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

Exclusion Criteria

• •Female subjects: Pregnancy or lactation
• •Drug addicts, alcoholics
• •AIDS, HIV-positive or infectious hepatitis
• •Conditions which exclude a participation or might influence the test reaction/evaluation
• •Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area
• •One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases
• •Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years
• •Insulin-dependent diabetes mellitus
• •Electronic implant (e.g. pace maker, insulin pump, hearing aid, and the like) that cannot be removed during irradiation
• •Documented allergies to cosmetic products and/or ingredients
• •Active skin disease at the test area
• •Irregularly tanned skin in the test area
• •Medical history of dysplastic nevi, melanoma or other skin carcinoma
• •Medical history of abnormal response to sunlight
• •Regular use of tanning beds (more than 10 times within the last 6 months)
• •Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation
• •Usage of medication with known photo-toxic and/or photo-sensitizing potential (e.g. some antibiotics, blood pressure regulating agents and antidepressants agents; hypericum perforatum) within the last 14 days prior to the start of the study and/or throughout the entire course of the study
• •Any topical medication at the test area within the last 7 days prior to the start of the study and/or throughout the entire course of the study
• •Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study and/or throughout the entire course of the study
• •Systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study and/or throughout the entire course of the study